NCT04547205 A Study of Anti-VEGFR2 AK109 in Subjects With Advanced Solid Tumors Status COMPLETED Phase PHASE1
NCT04547101 A Study of AK104 in Subjects With Locally Advanced Unresectable or Metastatic MSI-H/dMMR Solid Tumors Status TERMINATED Phase PHASE2
NCT04444167 A Study of Anti-PD-1/CTLA-4 Bispecific AK104 Plus Lenvatinib in First-line Advanced Hepatocellular Carcinoma Status COMPLETED Phase PHASE1/PHASE2
NCT04444141 A Study of PD-1/CTLA-4 Bispecific AK104 in Relapsed or Refractory Peripheral T-cell Lymphoma Status TERMINATED Phase PHASE1/PHASE2
NCT04380805 A Study of AK104, a PD-1/CTLA-4 Bispecific Antibody in Subjects With Recurrent/Metastatic Cervical Cancer Status COMPLETED Phase PHASE2
NCT04358432 A Study of PCSK9 Inhibitor AK102 in Patients With Hypercholesterolemia Status COMPLETED Phase PHASE2
NCT04220307 A Study of a PD-1/CTLA-4 Bispecific Antibody AK104 in Patients With Metastatic Nasopharyngeal Carcinoma Status COMPLETED Phase PHASE2
NCT04173793 A Study of PCSK9 Inhibitor AK102 in Patients With Heterozygous Familial Hypercholesterolemia (HeFH) Status COMPLETED Phase PHASE2
NCT04173637 Clinical Study of AK101 in Subjects With Moderate to Severe Plaque Psoriasis Status COMPLETED Phase PHASE2
NCT04173403 A Long-term Study of AK102 in Patients With Hypercholesterolemia Status COMPLETED Phase PHASE2
NCT04172571 A Study of the Combination of Anti-PD-1 AK105 and Anlotinib in First-line Hepatocellular Carcinoma (HCC) Status COMPLETED Phase PHASE2
NCT04172506 A Study to Evaluate the Efficacy and Safety of Anti-PD-1 Antibody AK105 in Patients With Selected Advanced Solid Tumors Status COMPLETED Phase PHASE1/PHASE2
NCT04172454 Safety and Efficacy of AK104, a PD-1/CTLA-4 Bispecific Antibody, in Selected Advanced Solid Tumors Status COMPLETED Phase PHASE1/PHASE2
NCT04172233 A Clinical Study of AK101 in Subjects With Moderate to Severe Plaque Psoriasis Status COMPLETED Phase PHASE1/PHASE2
NCT03933293 A Study to Evaluate the Safety and Efficacy of the PCSK9 Inhibitor AK102 in Patients With HoFH Status COMPLETED Phase PHASE2
NCT03866993 A Study of Anti-PD-1 AK105 in Patients With Metastatic Squamous Non-small Cell Lung Cancer Status COMPLETED Phase PHASE3
NCT03866980 A Study of Anti-PD-1 AK105 in Patients With Metastatic Nonsquamous Non-small Cell Lung Cancer Status TERMINATED Phase PHASE3
NCT03866967 A Study of Anti-PD-1 AK105 in Patients With Metastatic Nasopharyngeal Carcinoma Status COMPLETED Phase PHASE2
NCT03852251 A Study of AK104, a PD-1/CTLA-4 Bispecific Antibody, for Advanced Solid Tumors or With mXELOX/XELOX as First-line Therapy for Advanced Gastric or GEJ Adenocarcinoma Status COMPLETED Phase PHASE1/PHASE2